Arrowhead Pharmaceuticals (ARWR) Competitors $16.42 +0.36 (+2.24%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BBIO, VRNA, BPMC, ROIV, GRFS, LEGN, ELAN, RVMD, RGC, and RYTMShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Regencell Bioscience (RGC), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. Its Competitors BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Regencell Bioscience Rhythm Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ:ARWR) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Which has preferable earnings & valuation, ARWR or BBIO? BridgeBio Pharma has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$545.21M4.16-$599.49M-$1.40-11.73BridgeBio Pharma$221.90M39.63-$535.76M-$4.09-11.25 Do analysts rate ARWR or BBIO? Arrowhead Pharmaceuticals presently has a consensus price target of $43.71, suggesting a potential upside of 166.23%. BridgeBio Pharma has a consensus price target of $61.35, suggesting a potential upside of 33.39%. Given Arrowhead Pharmaceuticals' higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ARWR or BBIO? Arrowhead Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Does the media favor ARWR or BBIO? In the previous week, BridgeBio Pharma had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 23 mentions for BridgeBio Pharma and 15 mentions for Arrowhead Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.45 beat Arrowhead Pharmaceuticals' score of 0.24 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is ARWR or BBIO more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% BridgeBio Pharma -329.25%N/A -85.69% Do insiders & institutionals have more ownership in ARWR or BBIO? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBridgeBio Pharma beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.26B$2.98B$5.45B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-11.6918.0129.9924.99Price / Sales4.16174.97375.7976.03Price / CashN/A41.8335.9458.58Price / Book10.667.238.125.66Net Income-$599.49M-$54.43M$3.25B$265.39M7 Day Performance3.08%0.07%0.96%2.45%1 Month Performance-6.39%5.31%2.71%1.81%1 Year Performance-36.48%10.29%28.13%24.02% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.8212 of 5 stars$16.42+2.2%$43.71+166.2%-35.8%$2.26B$545.21M-11.69400Earnings ReportAnalyst RevisionBBIOBridgeBio Pharma4.719 of 5 stars$47.75+0.8%$61.18+28.1%+92.1%$9.07B$127.42M-13.53400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.8765 of 5 stars$105.47+0.3%$109.00+3.3%+439.7%$8.55B$118.54M-52.7430Earnings ReportUpcoming EarningsInsider TradeBPMCBlueprint Medicines0.6906 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.3632 of 5 stars$11.51+1.8%$16.50+43.4%+13.6%$7.82B$29.05M-46.04860GRFSGrifols3.287 of 5 stars$10.72-0.6%$10.30-3.9%+43.3%$7.37B$7.81B9.1623,822Analyst ForecastLEGNLegend Biotech3.8484 of 5 stars$38.45-0.9%$73.33+90.7%-32.0%$7.07B$728.30M-65.172,609News CoveragePositive NewsUpcoming EarningsAnalyst RevisionELANElanco Animal Health3.3476 of 5 stars$14.07+2.1%$16.17+14.9%+32.4%$6.99B$4.43B19.029,000Trending NewsEarnings ReportRVMDRevolution Medicines4.4482 of 5 stars$37.18+1.5%$68.91+85.3%-17.3%$6.93BN/A-9.30250News CoverageEarnings ReportAnalyst ForecastRGCRegencell Bioscience0.156 of 5 stars$13.76+6.1%N/AN/A$6.80BN/A0.0010Positive NewsRYTMRhythm Pharmaceuticals4.0837 of 5 stars$90.24+2.2%$91.93+1.9%+112.3%$5.74B$136.86M-32.11140Earnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Regencell Bioscience Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
